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Abstract: Synthetic cathinones belong to the most often seized new psychoactive substances on
an international level. This study investigated the toxicometabolomics, particularly the in vitro
metabolism of 2-(methylamino)-1-(4-methylphenyl)-1-pentanone (4-MPD) and 2-(ethylamino)-1-(4-
methylphenyl)-1-pentanone (4-MEAP) in pooled human liver microsomes (pHLM) using untargeted
metabolomics techniques. Incubations were performed with the substrates in concentrations ranging
from 0, 12.5, and 25 µM. Analysis was done by means of high-performance liquid chromatography
coupled to high-resolution mass spectrometry (HPLC-HRMS/MS) in full scan only and the obtained
data was evaluated using XCMS Online and MetaboAnalyst. Significant features were putatively
identified using a separate parallel reaction monitoring method. Statistical analysis was performed
using Kruskal-Wallis test for prefiltering significant features and subsequent hierarchical clustering,
as well as principal component analysis (PCA). Hierarchical clustering or PCA showed a distinct
clustering of all concentrations with most of the features z-scores rising with the concentration of
the investigated substances. Identification of significant features left many of them unidentified
but revealed metabolites of both 4-MPD and 4-MEAP. Both substances formed carboxylic acids,
were hydroxylated at the alkyl chain, and formed metabolites after combined hydroxylation and
reduction of the cathinone oxo group. 4-MPD additionally formed a dihydroxy metabolite and a
hydroxylamine. 4-MEAP was additionally found reduced at the cathinone oxo group, N-dealkylated,
and formed an oxo metabolite. These findings are the first to describe the metabolic pathways
of 4-MPD and to extend our knowledge about the metabolism of 4-MEAP. Findings, particularly
the MS data of the metabolites, are essential for setting up metabolite-based toxicological (urine)
screening procedures.
Keywords: untargeted metabolomics; 4-MPD; 4-MEAP; HPLC-HRMS/MS; metabolism
1. Introduction
Synthetic cathinones, derived from naturally occurring alkaloids of Catha edulis (Vahl)
Forssk. ex Endl., are one of the biggest groups of new psychoactive substances (NPS).
Mainly during the last two decades, a continuous flow of novel synthetic cathinones was
seized by customs all over the world [1]. As classified by Simmler et al. [2], cathinones
have a distinct but diverse pharmacology, which allow the deduction of structure–activity
relationships on the one hand but leave an uncertainty about the pharmacology of new
cathinones on the other hand.
Besides their often-unknown pharmacological potency, a widely occurring problem is
the false declaration of NPS sold online. 2-(Methylamino)-1-(4-methylphenyl)-1-pentanone
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(4-MPD, Figure 1A) is a prime example as it occurred the first time on the markets during
the last decade. Previously published studies performed by Hamby et al. [3] [4] revealed a
false declaration of 4-MPD, which turned out to be 2-(ethylamino)-1-(4-methylphenyl)-1-
pentanone (4-MEAP, Figure 1B) instead.
Metabolites 2021, 11, x FOR PEER REVIEW 2 of 14 
 
 
during the last decade. Previously published studies performed by Hamby et al. [3] 
[4]revealed a false declaration of 4-MPD, which turned out to be 2-(ethylamino)-1-(4-
methylphenyl)-1-pentanone (4-MEAP, Figure 1B) instead. 
 
Figure 1. Chemical structures of the investigated synthetic cathinones. (A) = 4-MPD and (B) = 4-
MEAP. 
4-MEAP was first reported to the Early Warning System of the European Monitoring 
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Distinct pharmacological data has not yet been reported for 4-MPD and 4-MEAP, but two 
case reports of misuse were published for 4-MEAP. Both individuals showed symptoms 
of increased dopaminergic and adrenergic activity including severe agitation and tachy-
cardia but no signs of serotonergic activity such as mydriasis, hypertension, or pyrexia 
[5]. This is in accordance with known structure-activity relationships [2]. In 2019, another 
fatal case describing co-misuse of 4-MEAP was reported [6]. 
In vitro metabolism studies using pooled human liver microsomes (pHLM) coupled 
with in silico biotransformation predictions were additionally performed. pHLM is one 
of the most commonly applied metabolism models for the investigation of the metabolism 
of drugs [7]. Several earlier publications showed that this model is also well suited for the 
investigation of the metabolism of cathinone-based drugs of abuse [8,9]. These incubations 
revealed three metabolites in vitro (N-deethyl-, dihydro-, and dihydro-HO-4-MEAP) of 
which two metabolites (N-deethyl- and dihydro-4-MEAP) were confirmed in post-mor-
tem human urine. Concerning 4-MPD, no case reports were published so far. 
Untargeted metabolomics (UM) represents an approach to perform analyses of the 
metabolome by using computational peak detection and subsequent statistical evaluation 
across multiple study groups [10–12]. Previous studies revealed that UM is well suited to 
investigate the toxicometabolomics of NPS in vitro [12–15]. Elucidating the metabolism of 
emerging compounds such as NPS is a prerequisite for setting toxicological screening pro-
cedures e.g., in case of suspected intoxications or abuse [16,17]. The present study aimed, 
therefore, to first synthesize 4-MPD as well as 4-MEAP and afterwards elucidate their tox-
icometabolomics, particularly their metabolism in pooled human liver microsomes by 
means of liquid chromatography coupled to high-resolution Orbitrap mass spectrometry 
and UM. 
2. Results and Discussion 
2.1. Infrared Spectroscopy 
Raw spectra in text format and the R script used to plot them can be found on GitHub 
(github.com/saskema/4mpd4meapphlm). Infrared spectroscopy (IR) is a valuable tech-
nique for the determination of functional groups and differentiation between similar sub-
stances by comparing fingerprinting regions. In direct comparison, both infrared spectra 
showed high similarity in peak location as expected (Figures S1 and S2). Strong aryl-car-
bonyl stretches (4-MPD: 1686 cm−1, 4-MEAP: 1689 cm−1) and an overlapping region of ali-
phatic and aromatic C-H stretching and amine salt NH2+ stretching (3000–2600 cm−1) rep-
resent the most characteristic bands for cathinone salts. The distinct single NH2+ defor-
mation band at 1606 cm−1 additionally confirms the presence of secondary amine salts [18]. 
No IR data was published for 4-MEAP before but wavenumbers for 4-MPD were in ac-
cordance with previous publications [19,20]. Functional groups are identical and therefore 
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aimed, therefore, to first synthesize 4-MPD as well as 4-MEAP and afterwards elucidate
their toxicometabolomics, particularly their metabolism in pooled human liver microsomes
by means of liquid chromatography coupled to high-resolution Orbitrap mass spectrometry
and UM.
2. Results and Discussion
2.1. Infrared Spectroscopy
Raw spectra in text format and the R script used to plot them can be found on
GitHub (github.com/saskema/4mpd4meapphlm). Infrared spectroscopy (IR) is a valuable
technique for the determination of functional groups and differentiation between similar
substances by comparing fingerprinting regions. In direct comparison, both infrared
spectra showed high similarity in peak location as expected (Figures S1 and S2). Strong
aryl-carbonyl stretches (4-MPD: 1686 cm−1, 4-MEAP: 1689 cm−1) and an verlapping
region of aliphatic and aromatic C-H stretching and ami e salt NH2+ stretching (3000–
2600 cm−1) represent the most characteristic bands for cathinone salts. The distinct single
NH2+ deforma ion b nd at 1606 cm−1 additionally confirms the presence of secondary
amine salts [18]. No IR dat was pub ished or 4-MEAP befor but wavenumbers for 4-MPD
were in accord nce with previous publications [19,20]. Functional groups are identical and
therefore the igh s milarity found in the spectra was not surprising. Differentiation of
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both substances was only achieved by subtle differences in intensity and peak position in
the fingerprinting region.
Concerning the identity and purity of the compounds, the IR analysis assured that
both compounds contain none to neglectable amounts of impurities, since 4-MPD matched
exactly the above-mentioned reference spectra. 4-MEAP merely differs in its alkyl sub-
stitution at the amine moiety leading to minimal expectable variation concerning the
IR-spectrum, such as the ratio of the peaks at 1467 and 1452 cm−1, indicating aliphatic
C-H bending, as well as the intensity of the peaks at 2785 and 2728 cm−1 indicating C-H
stretching. Additionally, due to the in-house synthesis of both compounds, the occurrence
of highly similar structural isomers is highly unlikely.
2.2. Untargeted Metabolomics
Files and metadata reported in this paper are available via Metabolights and the
study identifier MTBLS2218. R commands as obtained from MetaboAnalyst to reproduce
statistical evaluation can be found on GitHub (github.com/saskema/4mpd4meapphlm).
Heatmaps containing z-scores of the features’ abundances and dendrograms after hierar-
chical clustering are displayed in Figure 2, scores after PCA in Figure 3, and loadings after
PCA are shown in Figure S3.
The following samples were determined as outlier and needed to be removed from
further evaluations of the study. QC 1 (quality control injection 1, a pooled sample obtained
by mixing an aliquot of all samples) after analysis using reversed phase chromatography
and positive ionization mode, High 5 (sample 5 from group High) and QC 8 after analysis
using normal phase chromatography and positive ionization mode (incubations of 4-MPD).
QC 2 after analysis using reversed phase chromatography and positive ionization mode,
High 4 and QC 1, 7, and 8 after analysis using normal phase chromatography and positive
ionization mode (incubations of 4-MEAP). The decision for each sample was made by
inspecting both the hierarchical clustering, as well as their clustering in PCA scores. Further
inspection of the excluded samples revealed increased instrument variability. However, the
presented data is shown to be consistent and still revealed significant features as discussed
in the following sections.
Concerning 4-MPD, the hierarchical clustering mostly revealed a high distance of
samples from group Blank to those from other groups in analyses using positive ionization
mode (Figure 2A,B). While samples from group High did also form an isolated cluster,
samples from group Low and QC overlapped with one sample. This overlap can be
explained by the fact that the sample that forms group QC after multiple injections is
pooled from each of the other samples. Given the equally increased concentration of
4-MPD from group Blank to group High, the concentration of analytes in group QC
approximately corresponds to that of group Low. These results mainly correspond by the
z-scores of the features’ abundances given in the heatmap. Merely M162T725 in Figure 2A
showed z-scores that do not seem to correlate with sample groups. Given the fact, that
its z-scores are not equally distributed throughout group QC, it is most likely this that
these observations are caused by batch effects [21]. Regarding the analysis using normal
phase chromatography and negative ionization mode, samples of group Blank and High
are clustered as described above (Figure 2C). However, since only three significant features
were found and the investigated synthetic cathinones with their high concentrations are
not sufficiently ionized in negative mode, their clustering is less clear compared to analysis
in positive mode.
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tive ionization mode (Figure 2D) have comparatively high z-scores in group QC. This 
might be explained by ion enhancement, due to the pooling of all samples to obtain sam-
ples of group QC [22]. 
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The results of 4-MEAP after hierarchical clustering (Figure 2D–F) are more or less the
same as described for 4-MPD. It is notable that the features M144T764, M189T31, M245T360,
and M663T634 after analysis using reversed phase chromatography and positive ionization
mode (Figure 2D) have comparatively high z-scores in group QC. This might be explained
by ion enhancement, due to the pooling of all samples to obtain samples of group QC [22].
The results of PCA corresponded to those obtained after hierarchical clustering, with
groups Blank and High forming distinct clusters and group Low and group QC overlapping
(Figure 3A–F). Nevertheless, the overlap of one QC sample with group Blank in Figure 2A
was not observed after PCA (Figure 3A).
2.3. Identification of Significant Features
Results of the identification of significant features are summarized in Tables S2–S5.
MS2 spectra of significant features, available as indicated in Tables S2–S5 in the supple-
mentary data, can as well be found on GitHub (github.com/saskema/4mpd4meapphlm)
in mzXML format. However, for quick access and interpretation, all spectra of 4-MPD,
4-MEAP, and their metabolites can be found in Figures S4 and S5 with their tentative
structures and proposed fragmentation patterns. Isotopes, adducts, and artifacts that were
annotated by CAMERA were not further analyzed. Each of the remaining features were
analyzed using the parallel reaction monitoring (PRM) method as described above. Regard-
ing their identification level as proposed by Sumner et al. [23], all identified metabolites
of 4-MPD and 4-MEAP were putatively identified by deduction from the spectra of the
parent compounds, leading to a classification level of 3. All of the following masses used
to describe ions and fragments are theoretical masses.
2.3.1. 4-MPD
In total, 5 metabolites, 8 artifacts, and 11 isotopes could be putatively identified
(Tables S2 and S3). The fragmentation pattern of 4-MPD with the protonated molecular
ion at m/z 206.1539 (C13H20ON) was in accordance with a previous characterization by
Apirakkan et al. [24] (M206T264/M206T297 in Figure S4). Water loss (−18.0100 u) af-
ter elimination of the cathinone oxo group resulted in the fragment ion at m/z 188.1433
(C13H18N), further sigma bond cleavage led to the fragment ion at m/z 146.0964 (C10H12N).
Elimination of the amine moiety of 4-MPD resulted in the fragment ion at m/z 175.1117
(C12H15O). Additionally, the fragment after benzyl cleavage with fragment ion at m/z
105.0707 (C8H9) and the rather unspecific tropylium ion with m/z 91.0542 (C7H7) were
characteristic for this substance.
The metabolite formed after hydroxylation of the alkyl chain of 4-MPD (M222T357
in Figure S4) with protonated m/z 222.1488 (C13H20O2N) was putatively identified by a
second water loss resulting in the fragment ion with m/z 186.1277 (C13H16N). The tropylium
ion with m/z 91.0542 (C7H7) ruled out a hydroxylation at the phenyl ring, making an alkyl
hydroxylation most likely. N-oxidation of 4-MPD (M222T78 in Figure S4) resulted in the
same precursor ion with m/z 222.1488 (C13H20O2N). The conclusion of an N-oxidation
rather than a hydroxylation of 4-MPD was drawn due to the fact that a second water
loss was not observed and the fragment ion at m/z 162.0917 (C10H12ON) ruled out a
hydroxylation of the alkyl chain. Additionally, the fragment ion with m/z 119.0491 (C8H7O)
formed after benzylic scission ruled out a hydroxylation of the phenyl ring. At last, the
metabolite formed after N-oxidation eluted earlier than 4-MPD after using normal phase
chromatography, which is in accordance with similar observations concerning hydroxyl
amines using reversed phase chromatography [25]. All other metabolites were following
the same fragmentation pattern and thus putatively identified accordingly.
2.3.2. 4-MEAP
In total, 6 metabolites, 10 artifacts, 12 isotopes, and 1 adduct could be putatively
identified (Tables S4 and S5). The fragmentation pattern of 4-MEAP with the protonated
molecular ion at m/z 220.1695 (C14H22ON) (M220T274/M220T288 in Figure S5) was in
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accordance with Hamby et al. [3]. Similar to 4-MPD an initial water loss after the elim-
ination of the cathinone oxo group led to the formation of the fragment ion with m/z
202.1590 (C14H20N). Further sigma bond cleavage led to the fragment ion with m/z 160.1120
(C11H14N) and a benzylic scission led to formation of the fragment ion with m/z 105.0706
(C8H9). Again, the formation of a tropylium ion with m/z 91.0542 (C7H7) was observed.
Most of the metabolites of 4-MEAP were identified accordingly to 4-MPD and their fragmen-
tation pattern was the same as observed for 4-MPD. However, some metabolic pathways
of 4-MEAP were not observed for 4-MPD. The metabolite formed after N-deethylation
(M192T258/M192T333 in Figure S4) with protonated m/z 192.1382 (C12H18ON) was identi-
fied by the fragment ion with m/z 132.0807 (C9H8N2). This fragment represents the parent
ion after water elimination and further alkyl elimination. Compared to the spectrum
of 4-MEAP, the fragment is shifted by C2H4 (−28.0313 u), while the fragment formed
after water elimination and benzylic scission with m/z 105.0698 (C8H9) and the tropylium
ion with m/z 91.0542 (C7H7) remained the same. Reduction of the cathinone oxo group
(M222T277/M222T314 in Figure S4) resulted in the metabolite with the protonated m/z
222.1852 (C14H24O2N). The reduction was putatively identified by the fragment ion with
m/z 204.1746 (C14H22N) formed after elimination of water and the fragment ion with m/z
161.1199 (C11H15N) formed after elimination of the alkyl chain. The fact that both frag-
ments are shifted by at least one hydrogen implies that the initial elimination of water
did not result in the formation of an azirine ring as proposed by Franski et al. [26] earlier.
At last, the formation of an oxo group (M234T92 in Figure S4) was observed leading to
the metabolite with protonated m/z 234.1488 (C14H20O2N). In contrast to the spectra to all
of the other metabolites, the oxo metabolite did not perform an initial elimination of the
cathinone oxo group. Instead, the fragment ion after benzylic scission with m/z 119.0491
(C8H7O) is present with the highest abundance except for the parent ion. This might be
explained by assuming the oxo group to be in γ-position to the cathinone oxo group. It
would lead to a hydrogen bond with the protonated amine moiety that further prevents
the elimination of the cathinone oxo group.
2.4. Proposed Metabolic Pathways
The metabolic pathways of 4-MPD and 4-MEAP are shown in Figures 4 and 5.
Both compounds share several metabolic steps such as hydroxylation of the alkyl chain
(M222T357 in Figure 4 and M236T193/M236T335 in Figure 5), formation of a carboxylic
acid (M236T186 in Figure 4 and M250T197/M250T445 in Figure 5) and reduction of the
cathinone oxo group in combination with hydroxylation of the benzylic position (M224T173
in Figure 4 and M238T195/M238T367 in Figure 5). In case of 4-MPD, additional N-oxidation
(M222T78 in Figure 4) as well as hydroxylation of the alkyl chain in combination with hy-
droxylation of the benzylic position (M238T94 in Figure 4) was detected. Although being a
commonly detected metabolite for cathinones, the intermediate reduction of the cathinone
oxo group was not detected by the peak picking algorithm [6,27]. Manual inspection of the
extracted ion chromatograms revealed that it is presumably overlapped with a 13C2-isotope
at 208.1657 (C1213C2H21NO), which was most likely not properly resolved from that of the
dihydro metabolite with its protonated ion at m/z 208.1701 (C13H22NO) (see Figure S6).
This observation was already described earlier with other synthetic cathinones [12,28]. Con-
cerning 4-MEAP, an additional formation of an oxo group at the alkyl chain was detected
(M234T92 in Figure 5), as well as dealkylation of the amine moiety (M192T258 in Figure 5),
and reduction of the cathinone oxo group (M222T277/M222T314 in Figure 5).
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Figure 5. Proposed metabolic pathways of 4-MEAP in pHLM. Every metabolite is labeled by
its feature identifier as detected within untargeted metabolomics analysis. R = reversed phase
chromatography; N = normal phase chromatography.
These metabolic steps are in accordance with earlier publications investigating the
metabolism of similar compounds such as 4-chloroethcathinone, N-ethylnorpentylone, N-
ethylhexedrone (NEH), and 4-fluoro-alpha-pyrrolidinohexiophenon in pooled human liver
S9 fraction, human blood, or human urine [27]. N-Dealkylation, reduction of the cathinone
oxo group, and hydroxylation of the alkyl chain were detected for NEH amongst others
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in this study. The formation of carboxylic acid in benzylic position was also described
by Olesti et al. earlier [29]. Concerning 4-MEAP, its metabolism was already described
by Benedicte et al. [6]. They detected N-deethylation, as well as benzylic hydroxylation
and further reduction of the cathinone oxo group. However, hydroxylation of the alkyl
chain, further oxidation forming an oxo group, as well as formation of a carboxylic acid in
benzylic position are metabolic pathways were not found.
It is notable that 4-MPD did not form a dealkyl metabolite although this step is
described as one of the most common metabolic pathways for synthetic cathinones [28].
This finding excludes the occurrence of a common metabolite of 4-MPD and 4-MEAP which
might be misleading in some toxicological analyses. However, one has to remember that
the here presented data are in vitro data, making the occurrence of a dealkyl metabolite of
4-MPD in vivo still possible. Additionally, unlike other NPS such as synthetic cannabinoids,
that are extensively metabolized and often form structurally identical metabolites, synthetic
cathinones are also excreted unchanged. The parent mass of the feature M192T304 (Table S3)
might indicate to a possible dealkyl metabolite of 4-MPD, although the abundance of
obtained MS/MS spectra was too low to allow a final conclusion.
3. Materials and Methods
3.1. Chemicals and Reagents
All chemicals used for syntheses were obtained from Sigma Aldrich (Taufkirchen,
Germany). Hydrochloric acid gas in 2-propanol was prepared by gassing isopropanol with
hydrogen chloride (generated from the reaction between conc. H2SO4 and sodium chloride)
in the laboratory. NADP-Na2, acetonitrile (LC-MS grade), and methanol (LC-MS grade)
were obtained from VWR (Darmstadt, Germany), MgCl2, K2HPO4, KH2PO4, superoxide
dismutase, isocitrate dehydrogenase, isocitrate, ammonium formate, ammonium acetate,
and formic acid from Sigma (Taufkirchen, Germany). Water was purified with a Millipore
filtration unit (18.2 Ω × cm water resistance). pHLM (pool of 25 donors, 20 mg microsomal
protein/mL) were obtained from Corning (Amsterdam, The Netherlands). After delivery,
the pHLM were aliquoted, snap-frozen in liquid nitrogen, and stored at −80 ◦C until use.
3.2. Synthesis of 2-(Methylamino)-1-(4-Methylphenyl)-1-Pentanone (4-MPD) and
2-(Ethylamino)-1-(4-Methylphenyl)-1-Pentanone (4-MEAP)
A universally applicable synthesis pathway to obtain analogues of cathinone was
used to synthesize 4-MPD and 4-MEAP in three steps. The first step was a Friedel-Crafts
acylation under standard conditions using toluene and valeroyl chloride which formed
the phenone intermediate [30]. The second step was an alpha-carbonyl bromination which
formed the brominated phenone from the previously obtained phenone intermediate and
N-bromosuccinimide, followed by substitution with the appropriate alkylamine in the third
step [31]. Alkylamine addition was performed whilst cooling to prevent condensation and
possible pyrazine formation side reactions. Thereafter, hydrochloride salts were obtained
using a solution of hydrochloric acid gas dissolved in 2-propanol. All solvents used herein
were dried with 10% m/v 3Å molecular sieves for at least 24 h prior to use.
To obtain 1-(4-methylphenyl)pentane-1-one, toluene (50 mmol) in dichloromethane
(5 mL) was added drop wise to a mixture of aluminum chloride (55 mmol), valeroyl chloride
(52 mmol), and dichlormethane (20 mL) under stirring and cooling in an ice-bath. After
all the toluene solution was added, the resulting reaction mixture was stirred for further
2 h. The reaction mixture was poured on crushed ice, the organic phase was separated, and
the aqueous phase was re-extracted using dichloromethane (1 × 20 mL) and the combined
organic phases were sequentially washed with water, 1 M sodium hydroxide solution and
brine, and dried over anhydrous sodium sulfate. The solvent was evaporated to yield the
product as light amber oil (7.39 g, 42 mmol, 84% based on toluene). The isolated product
was used without further purification in the next step.
In order to obtain 2-bromo-1-(4-methylphenyl)pentane-1-one, 1-(4-methylphenyl)
pentan-1-one (42 mmol) was dissolved in acetonitrile (10 mL). N-Bromosuccinimide
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(47 mmol) and para-toluenesulfonic acid monohydrate (4.2 mmol) were added and the
reaction mixture was warmed to 60 ◦C water bath temperature and allowed to stir for
2 h. After cooling to room temperature, water (20 mL), dichloromethane (30 mL), and 1
M sodium hydroxide solution (20 mL) were added, the solution was stirred for 10 min
and the organic phase was separated and sequentially washed with 1M sodium hydroxide
solution and brine. The organic phase was dried over sodium sulfate, filtered on a Büchner
funnel, and further used as is in solution.
The final product 2-(methylamino)-1-(4-methylphenyl)-1-pentanone (4-MPD) hy-
drochloride was obtained after dissolving methylamine hydrochloride (60 mmol) and
NaOH (60 mmol) in water (6 mL) and slowly adding it to one half of the 2-bromo-1-(4-
methylphenyl)pentan-1-one solution (21 mmol) with strong stirring at −10 ◦C. After all the
methylamine solution had been added, the resulting reaction mixture was stirred for 1 h
after which water (20 mL) was added and stirring was continued for another 10 min. The
organic phase was separated and washed with water and brine, cooled in an ice bath, and
titrated with hydrochloric acid gas dissolved in 2-propanol until neutral. After freezing
overnight, the resulting product was filtered off, washed with cold anhydrous acetone, and
dried to a final yield of 0.41 g (2.0 mmol, 10%) of the hydrochloride salt as a white solid.
4-MEAP was synthesized as described for 4-MPD from 2-bromo-1-(4-methylphenyl)
pentan-1-one using ethylamine hydrochloride to obtain 0.35 g (1.6 mmol, 7.6%) of the
hydrochloride salt as a white solid.
3.3. Infrared Spectroscopy Apparatus and Analysis
IR spectra of the hydrochloride salts were acquired by solid KBr disks (ratio 1:300
w/w, substance/KBr, applied pressure 9×104 N) using a Bruker (Rheinstetten, Germany)
IFS 66 v/S under vacuum (7 mbar). IR spectra were recorded in a wavenumber range of
4000–600 cm−1 with a wavelength resolution of 4 cm−1 and 32 scans per spectrum. IR data
was handled using Bruker OPUS 5.5.
3.4. HPLC-HRMS/MS Apparatus
The analysis of UM samples was performed as described by Manier et al. [12] us-
ing a high-performance liquid chromatography system coupled to a high-resolution mass
spectrometer (HPLC-HRMS/MS) consisting of a Thermo Fisher Scientific (TF, Dreieich, Ger-
many) Dionex UltiMate 3000 RS pump coupled to a TF Q-Exactive Plus mass spectrometer.
The UltiMate 3000 RS system consisted of a degasser, a quaternary pump, an autosampler,
and an analytical column heater (column temperature 40 ◦C). Mass calibration was done
prior to analysis according to the manufacturer’s recommendations using external mass
calibration. Additionally, before each experiment, the spray shield and capillary were
cleaned. The performance of the column and the mass spectrometer was tested using a mix-
ture as described by Maurer et al. [32] prior to every experiment. Gradient reversed phase
elution was performed on a TF Accucore Phenyl-Hexyl column (100 × 2.1 mm, 2.6 µm).
The mobile phases consisted of 2 mM aqueous ammonium formate containing formic acid
(0.1%, v/v) and acetonitrile (1%, v/v, pH 3, eluent A), as well as 2 mM ammonium formate
in acetonitrile/methanol (1:1, v/v) containing formic acid (0.1%, v/v) and water (1%, v/v,
eluent B). The flow rate was set from 1–10 min to 500 µL/min and from 10–13.5 min to
800 µL/min using the following gradient: 0–1.0 min 99% A, 1–10 min to 1% A, 10–11.5 min
hold 1% A, 11.5–13.5 min hold 99% A. For normal phase elution, a Macherey-Nagel (Düren,
Germany) HILIC Nucleodur column (125 × 3 mm, 3 µm) was used. The mobile phases
consisted of 200 mM aqueous ammonium acetate (eluent C) and acetonitrile containing
formic acid (0.1%, v/v, eluent D). The flow rate was set to 500 µL/min using the following
gradient: 0–1 min 2% C, 1–5 min 20% C, 5–8.5 min 60% C, 8.5–10 min hold 60% C, 10–12
min hold 2% C. The injection volume for every analysis was 1 µL. The Q-Exactive Plus
was equipped with a heated electrospray ionization source (HESI-II) and was operated
in both, positive and negative ionization mode. The spray voltage was 3.50 kV, capillary
temperature, 320 ◦C; heater temperature, 320 ◦C; S-lens RF level, 50.0; sheath gas flow
Metabolites 2021, 11, 3 11 of 14
rate, 60 AU; auxiliary gas flow rate, 10 AU and sweep gas, 3 AU. Mass spectrometry for
UM was performed according to a previously optimized workflow by Manier et al. [33]
using full scan (FS) only. The resolution was 140,000 full width at half maximum (FWHM)
at mass to charge ration (m/z) 200; microscans, 1; automatic gain control target, 5 × 105;
maximum injection time, 200 ms; scan range, m/z 50–750; polarity negative or positive and
spectrum data type centroid. Thermo Fisher Scientific (TF, Dreieich, Germany) Xcalibur
version 4.0.27.19 software was used for data acquisition and manipulation. The analysis
was performed using a randomized sequence order with five injections of pure methanol
(Phenyl-Hexyl column) or eluent D (HILIC column) samples at the beginning of the se-
quence for apparatus equilibration, followed by five injections of the pooled QC sample.
Additionally, one QC injection was performed every five samples.
Statistically significant features were putatively identified using parallel reaction
monitoring (PRM): resolution, 70,000 FWHM; microscans, 1; automatic gain control target,
5 × 105; maximum injection time, 200 ms; isolation window, 0.4 m/z; normalized collision
energy, 10, 20, and 40 eV; spectrum data type, centroid.
3.5. Microsomal Incubations Using pHLM
Microsomal incubations were performed as initially described by Welter et al. [34]
with some modifications. Stock solutions of the investigated substances were prepared at
concentrations of 125 and 62.5 µM in 100 mM phosphate buffer. The incubation mixture of
each sample had a total volume of 50 µL and contained 90 mM phosphate buffer, 200 U/mL
superoxide dismutase, 5 mM isocitrate, 5 mM MgCl2, 1.2 mM NADP+, 0.5 U/mL isocitrate
dehydrogenase, 1 mg protein/mL pHLM, and 25 µM (further referred to as group High),
12.5 µM (further referred to as group Low), or 0 µM (further referred to as group Blank)
substrate. Each concentration was prepared in five replicates. The substrate was added
after preincubation of the incubation mixture in the orbital shaker (10 min, 37 ◦C, 200 rpm)
to incubate for another 60 min (37 ◦C, 200 rpm). Incubations were stopped by addition of
50 µL ice cold acetonitrile and centrifugation for 2 min at 14,000 U/min. The supernatant
was transferred to an MS vial and a pooled QC sample was prepared using 10 µL of each
prepared sample. All samples were analyzed using HPLC-HRMS/MS as described above.
3.6. Data Processing for Untargeted Metabolomics
The proprietary TF raw data format files were converted to the open data format
mzXML using ProteoWizard’s MSConvert (version 3.0.1) [35]. Subsequently, QC files were
used for peak detection parameter optimization as described by Manier et al. [33]. Peak
picking parameters that were used in this study are summarized in Table S1. Prepro-
cessing and statistical evaluation was conducted using XCMS Online (version 3.7.1) and
MetaboAnalyst (via https://www.metaboanalyst.ca/) (version 4.0). The converted MS
data sets of Blank, Low, High, and QC were uploaded, and the parameters were adjusted
according to the optimized values generated through the algorithm. Afterwards, features
with valid extracted ion chromatograms and p-values lower than or equal to 0.01 after
Kruskal-Wallis analysis were kept. Chromatograms were assumed valid when the peak
detection integrated gaussian-like chromatographic peaks rather than arbitrary baseline
fluctuation. Samples were also checked for within group outliers and removed from the
study in case of high deviation. The obtained feature table was subsequently uploaded
to MetaboAnalyst for further statistical evaluation. In MetaboAnalyst, missing value esti-
mation was skipped because in no case missing values were present. Data filtering was
skipped as well because in every case, less than 5000 features were submitted and therefore
a need to compress the data was not given. After log transformation, the data set was
submitted to multivariate statistical analysis. Hierarchical clustering was performed using
Euclidian distances and complete clustering. Color contrast in the corresponding heatmap
was set to “Heat Color”, samples were not reorganized, and normalized data was selected
to be displayed. Additionally, features were autoscaled for this analysis. Finally, a PCA
was performed to inspect the samples clustering in the corresponding score plots and the
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features’ influence on the clustering in the corresponding loading plots. The data set was
not scaled prior to PCA. Names of the features were adopted from XCMS Online using
“M” followed by the rounded mass and “T” followed by the retention time in seconds (e.g.,
“M206T264” as given in Table S2 for protonated 4-MPD at m/z 206.1543 and a retention
time of 264 s using reversed phase chromatography).
3.7. Identification of Significant Features
MS2 spectra were recorded using the above-mentioned PRM method to allow iden-
tification of significant features. Individual spectra were exported after subtracting the
baseline left and right of the peak. After conversion to mzXML format using ProteoWizard’s
MS Convert, spectra were imported to NIST MSSEARCH version 2.3. A library search for
identification was conducted using the following settings: spectrum search type, identity
(MS/MS); precursor ion m/z, in spectrum; spectrum search options, none; presearch, off;
other options, none. MS/MS search was conducted using the following settings: precursor
tolerance, ±5 ppm; product ion tolerance, ± 10 ppm; ignoring peaks around precursor,
± m/z 1. The search was conducted by using the following libraries: NIST 14 (nist_msms
and nist_msms2 sublibraries) and Wiley METLIN Mass Spectral Database. Metabolites of
the investigated NPS were putatively identified by interpreting their spectra in comparison
to those of the parent compounds.
4. Conclusions
Due to the high abundance and fluctuation of the NPS market, many NPS still lack
substantial pharmacological and toxicological characterization. We described the successful
synthesis the two cathinones 4-MPD and 4-MEAP and elucidated their in vitro metabolism
in pHLM by using untargeted toxicometabolomics in combination LC-HRMS/MS. For both,
4-MPD and 4-MEAP, five and six metabolites could be putatively identified, respectively.
The discussed analytical findings are essential to allow their detection in (urine) screening
procedures e.g., in case of intoxications.
Supplementary Materials: The following are available online at https://www.mdpi.com/2218-1
989/11/1/3/s1: Table S1: Peak picking and alignment parameters used for preprocessing of data
concerning 4-MPD and 4-MEAP, Table S2: Significant features of 4-MPD detected using reversed
phase chromatography. Table S3: Significant features of 4-MPD detected using normal phase chro-
matography, Table S4: Significant features of 4-MEAP detected using reversed phase chromatography,
Table S5: Significant features of 4-MEAP detected using normal phase chromatography, Figure S1:
FT-IR spectrum of 4-MPD HCl (KBr pellet), Figure S2: FT-IR spectrum of 4-MEAP HCl (KBr pellet),
Figure S3: Loadings of principal component analysis, Figure S4: LC–HRMS/MS spectra of 4-MPD
and its metabolites sorted by mass of their protonated molecule and retention time, Figure S5: LC–
HRMS/MS spectra of 4-MEAP and its metabolites sorted by mass of their protonated molecule
and retention time, Figure S6: Extracted ion chromatogram of two peaks assumed to be 4-MPD
isotope (13C2) and 4-MPD-M (dihydro-) taken from sample High 1 after analysis using reversed
phase chromatography and positive ionization.
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